DXP-106

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug NameDXP-106
Drug Alias NameDXP106DXP-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Interleukin-1 receptor accessory protein
TargetsInterleukin-1 receptor accessory protein
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSinglomics Biopharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai Singlomics Biopharmaceutical Co Ltd
Inactive CompaniesSinglomics Biopharmaceuticals Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A